Home » Clinical Trials » Location » Japan
Search Medical Condition
One Or Multiple Investigational Sites, Japan Clinical Trials
A listing of One Or Multiple Investigational Sites, Japan clinical trials actively recruiting patients volunteers.
Found (59375) clinical trials
NASH001 - Non-alcoholic Steatohepatitis (NASH) - CC-90001-NASH-001 - US
Primary Outcome Measures :Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis [ Time Frame: Up to approximately 52 weeks ]Assessment of liver fibrosis score by the NASH Clinical Research Network (CRN) scoring systemSecondary Outcome Measures :Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis and no worsening of steatohepatitis ...
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US
This is a single-arm, multi-cohort, multi-center, Phase 2 study to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell NHL. The study will enroll subjects in Europe and Japan with DLBCL NOS (de novo or tFL), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements ...
FREEDOM - Myelofibrosis - FEDR-MF-001 - US
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib. The primary objective of the study is to ...
Parkinson’s disease patients and their caregivers are needed for a Washington University School of Medicine research study.
Dr. Kevin Black will look at the safety and effectiveness of an investigational drug compared to placebo (inactive substance) in the treatment of Parkinson’s disease with psychosis. Participation in this study may last up to 12 weeks. There will be a screening visit lasting about 3 hours and up to ...
A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Primary Objective: To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD). Secondary Objectives: To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD. To compare the efficacy of IPX203 with ...
A Washington University research study seeks participants with Parkinson’s disease.
The purpose of the study is to determine how quickly a protein called Alpha-synuclein (a-syn) is cleared from the body in participants with Parkinson’s disease. A-syn is a major component of Parkinson’s disease. There are up to 7 study visits. Participation includes neurological/physical exam, vitals, blood draws and lumbar puncture ...
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of PD patients who continue to have dyskinesia on amantadine.
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
AHEP0731: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Liver Cancer
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00980460?term=AHEP0731&rank=1
